2. Signaling Pathways
  3. Neuronal Signaling
    Protein Tyrosine Kinase/RTK
  4. Trk Receptor

Trk Receptor

Tropomyosin related kinase receptor

Trk Receptor

Related Products

PDF 0.95 MB

Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).

TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.

The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.

Trk Receptor Isoform Specific Products:

Trk Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-153743
    Protein kinase inhibitor 4
    		Inhibitor
    Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively).
    Protein kinase inhibitor 4
  • HY-163366
    TRK-IN-28
    		Inhibitor
    TRK-IN-28 (compound 30f) is a TRK inhibitor with the IC50 values of 0.55 nM, 25.1 nM and 5.4 nM against TRKWT, TRKG595R and TRKG667C, respectively. TRK-IN-2 shows antiproliferative activity with IC50 values of 9.5, 3.7, 205.0 and 48.3 nM against Ba/F3-ETV6-TRKAWT, Ba/F3-ETV6-TRKBWT, Ba/F3-LMNA-TRKG595R and Ba/F3-LMNA-TRKAG667C, respectively.
    TRK-IN-28
  • HY-153745
    Protein kinase inhibitor 5
    		Inhibitor
    Protein kinase inhibitor 5 is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 inhibits cell viability.
    Protein kinase inhibitor 5
  • HY-144424
    Trk-IN-11
    		Inhibitor
    Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK (IC50 = 1.4, 1.8 nM, against TrkA, TrkAG595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease.
    Trk-IN-11
  • HY-157542
    CG428-NEG
    		Control
    CG428-NEG is a TRK degrader negative control. CG428 (HY-137465) inhibits cell growth and reduce TPM3-TRKA levels.
    CG428-NEG
  • HY-146518
    TRK-IN-13
    		Inhibitor
    TRK-IN-13 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-13 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-24).
    TRK-IN-13
  • HY-12866B
    (R)-Larotrectinib
    		Inhibitor
    (R)-Larotrectinib is a potent TRK inhibitor with an IC50 value of 28.5 nM for TrkA. (R)-Larotrectinib can be used for researching cancer, inflammatory and certain infectious diseases
    (R)-Larotrectinib
  • HY-144028
    Pan-Trk-IN-2
    		Inhibitor
    Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity.
    Pan-Trk-IN-2
  • HY-153189
    TrkB-IN-1
    		Agonist
    TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research.
    TrkB-IN-1
  • HY-150258
    TRK-IN-22
    		Inhibitor
    TRK-IN-22 (compound 11) is a TRK inhibitor. TRK-IN-22 (compound 11), a typical type I inhibitor, covers the ATP-binding pocket of TRKA.
    TRK-IN-22
  • HY-12327
    Trk-IN-1
    		Inhibitor
    Trk-IN-1 (example 9), a potent tropomyosin-related kinase (Trk) inhibitor, shows potency against TrkA (3.7 nM) and TrkB (94 nM), respectively.
    Trk-IN-1
  • HY-144321
    Trk-IN-9
    		Inhibitor
    Trk-IN-9 (Compound 12) is a potent inhibitor of TRK. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the apoptosis of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways. Trk-IN-9 has the potential for the research of NTRK-fusion cancers.
    Trk-IN-9
  • HY-P990749
    Luvagrobart
    		Inhibitor
    Luvagrobart is an anti-NGF human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Luvagrobart
  • HY-149912
    CZS-241
    		Inhibitor
    CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC50=2.6 nM). CZS-241 inhibits TRKA with an IC50 value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines.
    CZS-241
  • HY-144423
    Trk-IN-10
    		Inhibitor
    Trk-IN-10 (Compound 14j) is a potent inhibitor of TRK (IC50 = 0.86, 6.92 nM, against TrkA, TrkAG595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity.
    Trk-IN-10
  • HY-151945
    TRK II-IN-1
    		Inhibitor
    TRK II-IN-1 is a potent type II TRK inhibitor, with IC50s of 3.3, 6.4, 4.3 and 9.4 nM, for TRKA/B/C and TRKAG667C, respectively. TRK II-IN-1 also inhibits FLT3, RET, and VEGFR2/KDR/Flk-1 with IC50s of 1.3, 9.9, and 71.1 nM, respectively. TRK II-IN-1 can be used for the research of TRK driven cancers.
    TRK II-IN-1
  • HY-107854R
    N-Acetyl-5-hydroxytryptamine (Standard)
    		Activator
    N-Acetyl-5-hydroxytryptamine (Standard) is the analytical standard of N-Acetyl-5-hydroxytryptamine. This product is intended for research and analytical applications. N-Acetyl-5-hydroxytryptamine is a Melatonin precursor, and that it can potently activate TrkB receptor.
    N-Acetyl-5-hydroxytryptamine (Standard)
  • HY-126287
    JND4135
    		Inhibitor
    JND4135 is a Type II TRK inhibitor with IC50 values of 2.79, 3.19, and 3.01 nM against TRKA, TRKB, TRKC, respectively. JND4135 can overcome resistance from TRK xDFG and other mutant forms in the BaF3 stable model, inhibiting phosphorylation of both WT and xDFG mutant TRKs, along with their downstream signaling molecules. JND4135 can induce G0/G1 phase arrest and apoptosis in BaF3–CD74-TRKA-G667C cells. JND4135 shows tumor growth inhibition activity in the BaF3-CD74-TRKA-G667C mouse xenograft model.
    JND4135
  • HY-139891
    Trk-IN-6
    		Inhibitor
    Trk-IN-6 shows excellent in vitro potency on a panel of TRK mutants (IC50 = 0.2-0.7 nM).
    Trk-IN-6
  • HY-156470
    Multi-kinase-IN-6
    		Inhibitor
    Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect.
    Multi-kinase-IN-6
Cat. No. Product Name / Synonyms Application Reactivity
Trk Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.